PSMA靶向混合示踪剂PSMA-I&F的合成及临床前表征:用于前列腺癌核素与荧光成像
本研究合成并评价了基于PSMA-I&T的混合示踪剂PSMA-I&F(DOTAGA-k(Sulfo-Cy5)-y-nal-k-Sub-KuE),用于前列腺癌的核素与荧光成像。在LNCaP细胞中,PSMA-I&F及其natGa-/natLu-复合物的PSMA亲和力保持高值且不受染料偶联影响(所有配体7.9 < IC50 < 10.5 nM)。体内实验显示68Ga/177Lu-PSMA-I&F血液清除仅因高血浆蛋白结合(94%-95%)而轻微延迟,注射后1小时非靶器官摄取极低,动态PET证实对LNCaP异种移植瘤和肾脏的PSMA特异性摄取。
要点
- PSMA-I&F及其natGa-/natLu-复合物保持高PSMA亲和力,IC50在7.9至10.5 nM之间。
- 68Ga/177Lu-PSMA-I&F血浆蛋白结合为94%-95%,血液清除仅轻微延迟。
- 注射后1小时肿瘤/血、肝、肠、肌肉比值分别为2.1、5.2、9.6、9.6,成像对比度优良。
核心结论
- 68Ga/177Lu-PSMA-I&F具有高PSMA靶向效率和良好药代动力学特征,可作为PSMA-I&T基础混合成像可行性的概念验证化合物。
研究设计与样本
- 在LNCaP细胞中通过竞争结合实验(IC50)和双示踪剂放射配体及荧光内化研究确定PSMA-I&F、参考PSMA-I&T及其natGa-/68Ga-和natLu/177Lu对应物的体外PSMA靶向效率。
- 在CB17 SCID小鼠和荷LNCaP异种移植瘤的SHO小鼠中分别进行生物分布和小动物PET成像研究,并辅以临床腹腔镜进行术中远红光荧光成像。
- 还对1只荷瘤动物进行全自动连续冷冻切片和荧光成像,以及对器官冷冻切片(肿瘤、肾脏、脾脏)进行PSMA免疫组化和荧光显微镜检查。
主要发现
- 与母体PSMA-I&T类似物相比,PSMA-I&F及其natGa-/natLu-复合物的PSMA亲和力保持高值且不受染料偶联影响(所有配体7.9 < IC50 < 10.5 nM)。
- 68Ga-和177Lu-PSMA-I&F的内化情况与上述观察相同。
- 体内68Ga-和177Lu-PSMA-I&F的血液清除仅因高血浆蛋白结合(94%-95%)而轻微延迟,注射后1小时已观察到非靶器官积累极低。
- 动态PET成像证实LNCaP异种移植瘤(4.5% ± 1.8 %ID/g)和肾脏(106% ± 23 %ID/g)的PSMA特异性摄取(通过共注射2-PMPA证明)。
- 注射后1小时肿瘤/本底比值分别为血2.1、肝5.2、肠9.6、肌肉9.6,在68Ga-PSMA-I&F PET和术中荧光成像中产生极好成像对比度;组织冷冻切片荧光成像可高分辨率可视化PSMA-I&F在器官内的分布并与免疫组化测定的PSMA表达相关。
关键数值与推荐
- 所有配体PSMA亲和力IC50在7.9至10.5 nM之间。
- 68Ga/177Lu-PSMA-I&F血浆蛋白结合为94%-95%。
- LNCaP异种移植瘤摄取为4.5% ± 1.8 %ID/g,肾脏摄取为106% ± 23 %ID/g。
- 注射后1小时肿瘤/本底比值:血2.1、肝5.2、肠9.6、肌肉9.6。
临床怎么用
- 68Ga/177Lu-PSMA-I&F可作为PSMA-I&T基础混合成像可行性的概念验证化合物。
- PSMA-I&T支架代表一种多功能的PSMA靶向前导结构,可相对直接地适配专用核素或混合成像剂的不同结构要求。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA)-targeted radiotracers 68Ga/177Lu-PSMA-I&T and 99mTc-PSMA-I&S (for i maging and s urgery) are currently successfully used for clinical PET imaging, radionuclide therapy, and radioguided surgery of metastatic prostate cancer. To additionally exploit the high sensitivity and spatial resolution of fluorescence imaging for improved surgical guidance, a PSMA-I&T-based hybrid tracer, PSMA-I&F (DOTAGA-k(Sulfo-Cy5)-y-nal-k-Sub-KuE), has been developed and evaluated. Methods: The in vitro PSMA-targeting efficiency of PSMA-I&F, the reference PSMA-I&T, and their corresponding natGa-/68Ga- and natLu/177Lu counterparts was determined in LNCaP cells via competitive binding assays (IC50) and dual-tracer radioligand and fluorescence internalization studies. Biodistribution and small-animal PET imaging studies were performed in CB17 SCID and LNCaP xenograft-bearing SHO mice, respectively, and complemented by intraoperative far-red fluorescence imaging using a clinical laparoscope. Additionally, fully automated serial cryosectioning and fluorescence imaging of 1 tumor-bearing animal as well as PSMA immunohistochemistry and fluorescence microscopy of organ cryosections (tumor, kidney, spleen) were also performed. Results: Compared with the parent PSMA-I&T analogs, the PSMA affinities of PSMA-I&F and its natGa-/natLu-complexes remained high and unaffected by dye conjugation (7.9 < IC50 < 10.5 nM for all ligands). The same was observed for the internalization of 68Ga- and 177Lu-PSMA-I&F. In vivo, blood clearance of 68Ga- and 177Lu-PSMA-I&F was only slightly delayed by high plasma protein binding (94%-95%), and very low accumulation in nontarget organs was observed already at 1 h after injection. Dynamic PET imaging confirmed PSMA-specific (as demonstrated by coinjection of 2-PMPA) uptake into the LNCaP xenograft (4.5% ± 1.8 percentage injected dose per gram) and the kidneys (106% ± 23 percentage injected dose per gram). Tumor-to-background ratios of 2.1, 5.2, 9.6, and 9.6 for blood, liver, intestines, and muscle, respectively, at 1 h after injection led to excellent imaging contrast in 68Ga-PSMA-I&F PET and in intraoperative fluorescence imaging. Furthermore, fluorescence imaging of tissue cryosections allowed high-resolution visualization of intraorgan PSMA-I&F distribution in vivo and its correlation with PSMA expression as determined by immunohistochemistry. Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. The PSMA-I&T scaffold represents a versatile PSMA-targeted lead structure, allowing relatively straightforward adaptation to the different structural requirements of dedicated nuclear or hybrid imaging agents.
引用
- Schottelius M, Wurzer A, Wissmiller K, et al. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. J Nucl Med. 2018. PMID: 30237214. doi:10.2967/jnumed.118.212720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。